Results 161 to 170 of about 5,952 (188)
Lipids, lipid-modifying drug targets with venous thromboembolism: a mendelian randomization study. [PDF]
Nie L, Han Y, Zheng F.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Abstract I26: Investigating the immune microenvironment in mouse models of pancreatic cancer
Cancer Research, 2019Abstract Pancreatic cancer is predicted to become the second most common cause of cancer death in the Western world by ~2025. The focus of our research has been to better understand the disease and identify more effective and targeted therapies, in particular, using genetically engineered mouse models, which develop pancreatic tumors ...
Karen Pickering +5 more
openaire +1 more source
I26 Laparoscopic-Assisted Insertion of a Peritoneal Dialysis Catheter
2013Peritoneal dialysis is an alternative to haemodialysis and is used to treat patients with end-stage renal disease. Different techniques have been developed for catheter placement. We describe a single-port laparoscopic technique which allows good visualization of the pelvis and accurate positioning of the peritoneal catheter, with a low complication ...
Salvatore Cascio +2 more
openaire +1 more source
I26 Registry: scientific resource
Journal of Neurology, Neurosurgery & Psychiatry, 2016The European Huntington’s disease Network’s (EHDN) REGISTRY study is an invaluable resource for scientists and researchers. REGISTRY is a clinical research platform that can expedite experimental medicine studies, biomarker development, and refine clinical assessments for HD.
openaire +1 more source
I26 Outpatient induction: Is it feasible?
International Journal of Gynecology & Obstetrics, 2009C. Benedetto +3 more
openaire +1 more source
I26 Alternatives to PGD: Non-invasive assessment of oocytes and embryos
Reproductive BioMedicine Online, 2013openaire +1 more source
A Collapsed Fingers Subdomain is the Basis for DNA Polymerase β I260M Mutator Activity
FASEB Journal, 2022Khadijeh S Alnajjar +2 more
exaly

